Recombinant Human FGFR3 alpha (IIIb) His-tag Protein, CF

Measured by its binding ability in a functional ELISA. Recombinant Human FGFR3 alpha (IIIb) His-tag Protein (Catalog # 11136-FR) binds to Recombinant Human FGF acidic/FGF1 (aa 16-155) Protein (232-FA) with an ED50 of 0.700-7.00 μg/mL.

2 μg/lane of Recombinant Human FGFR3 alpha (IIIb) His-tag Protein (Catalog # 11136-FR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-66 kDa.

• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human FGFR3 alpha (IIIb) His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Recombinant Human FGFR3 alpha (IIIb) His-tag (Catalog # 11136-FR) binds to Recombinant Human FGF acidic/FGF1 (aa 16-155) Protein (Catalog # 232-FA) with an ED₅₀ of 0.700-7.00 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human FGFR3 protein
  Glu23-Gly377, with a C-terminal 6-His tag
• Accession #: NP_001156685.1
• N-terminal Sequence: Glu23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 39 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-66 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human FGFR3 alpha (IIIb) His-tag Protein, CF

• CD333
• CEK
• EC 2.7.10
• FGF R3
• FGFR3
• fibroblast growth factor receptor 3
• HSFGFR3EX
• JTK4
• JTK4thanatophoric dwarfism

Background

Fibroblast growth factor receptor 1 (FGFR1) belongs to a family of type I transmembrane tyrosine kinases which mediate the biological functions of FGFs that are involved in a multitude of physiological and pathological cellular processes (1). The FGFR family is comprised of 4 structurally conserved members (FGFR1-4) all possessing and extracellular domain (ECD) with three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain (1, 2). The ECD of mature, full-length FGFR3 shares 92% amino acid sequence identity with mouse FGFR3. Alternative splicing generates multiple forms of FGFR1-3, each with unique signaling characteristics (1-3). For FGFR3, alternative splicing of the ECD, specifically the IgIII domain, results in IIIb, or IIIc isoforms (4). The FGFR splice variants also exhibit distinct and varying binding affinities for different FGF ligands (2). FGFRs mediate the FGF signaling cascade which regulate developmental processes including cellular proliferation, differentiation, and migration, morphogenesis, and patterning (5). FGFRs transduce the signals through three dominant pathways including RAS/MAPK, PI3k/AKT, and PLC gamma (6). FGFR3 is normally expressed in the tissues of the central nervous system, brain, kidney and testis, with the FGFR3A(IIIb) splice variant predominantly expressed in epithelial cells (7, 8). FGFR3 signaling is critical for bone growth regulation and mutations in FGFR3 or misregulation of FGFR3 mediated signaling is found in multiple skeletal dysplasias, with FGFR3A(IIIb) specifically upregulated in hepatocellular carcinoma but down regulated in colorectal cancer (1, 4, 8, 9).

1. Ornitz, D.M. and Itoh, N. (2015) Wiley Interdiscip Rev Dev Biol. 4:215.
2. Zhang, X. et al. (2006) J Biol Chem. 281:15694.
3. Ferguson, H.R. et al. (2021) Signaling. Cells 10:1201.
4. Holzmann, K. et al. (2012) J Nucleic Acids. 2012:950508.
5. Xie, Y. et al. (2020) Sig Transduct Target Ther 5:181.
6. Mossahebi-Mohammadi, M. et al. (2020) Front Cell Dev Biol. 18:79.
7. Sturla, L.M. et al. (2003) Br. J. Cancer 89:1276.
8. Paur, J. et al. (2015) Hepatology. 62:1767.
9. Teven, C.M. et al. (2014) Genes Dis. 1:199.

Bioinformatics

• Uniprot:
  • NP_001156685.1()